Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Oculis Holding AG (NASDAQ:OCS) saw strong trading volume on Friday . 54,091 shares were traded during trading, an increase of 52% from the previous session’s volume of 35,631 shares.The stock last traded at $17.83 and had previously closed at $17.18.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $29.20.

Oculis Stock Up 4.1 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The company’s 50-day simple moving average is $13.50 and its 200 day simple moving average is $12.43. The firm has a market cap of $724.14 million, a P/E ratio of -9.31 and a beta of 0.30.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Research analysts anticipate that Oculis Holding AG will post -2.19 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.